Showing posts with label Novelos. Show all posts
Showing posts with label Novelos. Show all posts
Mar 14, 2008
Novelos Therapeutics, Pivotal Phase 3 Lung Cancer Trial
Oct 2, 2007
development of NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer
October 1, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that Novelos, in collaboration with the Medical University of South Carolina (MUSC), was awarded a $150,000 competitive grant by the National Institutes of Health (NIH) under Phase I of the Small Business Technology Transfer (STTR) program. This grant will support further scientific development of NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track... Novelos' Press Release [PDF] -
Sep 11, 2007
Novelos Therapeutics, 5th U.S. Patent
Monday September 10, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that Novelos was issued U.S. Pat. No. 7,169,412 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track... Novelos Therapeutics' Press Release -
Subscribe to:
Posts (Atom)